Celgene raises full-year outlook on strong cancer drug sales

(Reuters) - Biotechnology firm Celgene Corp raised its full-year earnings forecast for the second time in three months after it reported a quarterly profit above analysts' estimates, as its cancer drugs, Revlimid and Abraxane, continued to post strong sales growth.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news